|Articles|March 1, 2019
- Pharmaceutical Executive-03-01-2019
- Volume 39
- Issue 3
Pharmaceutical Executive, March 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive March 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 7 years ago
Patient Advocacy: The Corporate Mandateabout 7 years ago
Patient Support Programs: Cost, Benefit, and Resourcingabout 7 years ago
Patients is a Virtueabout 7 years ago
What Does Patient Centricity Look Like?about 7 years ago
John Crowley: Living the Missionabout 7 years ago
Research Bonds Strengthenabout 7 years ago
Parallel Trade a Victim of Brexit Collateral Damageabout 7 years ago
Multiple Pharma Issues Top Congressional Agendaabout 7 years ago
Pharm Exec Joins MJH Portfolioabout 7 years ago
Cystic Fibrosis: The Importance of Patient AdvocacyAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
What Kinds of Disruption are GLP-1s Expected to Face
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
The Evolving Relationship Between FDA and Biotech
5